Kyverna Presents Registrational Trial Primary Analysis for Miv-cel in Stiff Person Syndrome Demonstrating Statistically Significant, Durable Clinical Benefit Across All Endpoints in an Oral, Late-Breaker Session at AAN Annual Meeting
Kyverna reported positive primary analysis from its registrational KYSA-8 trial of miv-cel in stiff person syndrome, demonstrating statistically significant improvements across all primary and secondary endpoints. A single dose of miv-cel achieved a median 46% improvement in walking speed at 16 weeks (p=0.0003), with all 26 patients discontinuing chronic immunotherapies.
Key figures
- Drug Name
- miv-cel (mivocabtagene autoleucel, KYV-101)
- Phase Of Trial
- Phase 2
- Patients dosed
- 26
- Primary endpoint p value
- 0.0003
- T25fw median improvement percent
- 46
- Patients discontinued immunotherapy
- 26
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.